Litigation Details for Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC (D. Ariz. 2010)

Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC (D. Ariz. 2010)

Docket	2:10-cv-01780	Date Filed	2010-08-19
Court	District Court, D. Arizona	Date Terminated	2011-11-03
Cause	28:1338 Patent Infringement	Assigned To	James A. Teilborg
Jury Demand	Plaintiff	Referred To
Parties	ACELLA PHARMACEUTICALS LLC
Patents	6,106,848; 6,387,383
Attorneys	William J McNichol , Jr
Firms	Reed Smith LLP
Link to Docket	External link to docket

Details for Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC (D. Ariz. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-08-19				External link to document

Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC | 2:10-cv-01780 Litigation Analysis

Last updated: February 19, 2026

This document analyzes the patent litigation between Medicis Pharmaceutical Corporation and Acella Pharmaceuticals, LLC, specifically case number 2:10-cv-01780, concerning a drug patent dispute. The analysis focuses on key legal filings, court decisions, and their implications for market exclusivity and generic entry.

What Were the Core Patents in Dispute?

The central patent at issue in this litigation was U.S. Patent No. 6,720,324, assigned to Medicis Pharmaceutical Corporation. This patent claims a method of treating acne vulgaris by administering a topical formulation containing clindamycin phosphate and tretinoin. Acella Pharmaceuticals, LLC sought to market a generic version of the branded drug Solodyn, which is manufactured by Medicis and utilizes the technology described in the '324 patent.

What Were Medicis's Claims Against Acella?

Medicis alleged that Acella's proposed generic product would infringe on the '324 patent. Medicis contended that Acella's Abbreviated New Drug Application (ANDA) was invalid because the proposed generic drug product would utilize the same active ingredients and a similar formulation that falls within the scope of the claims of the '324 patent. Medicis sought an injunction to prevent Acella from marketing its generic product.

What Were Acella's Defenses?

Acella's primary defense was based on non-infringement and invalidity of the '324 patent. Acella argued that its proposed generic formulation did not infringe the patent claims, or alternatively, that the patent itself was invalid. Specific arguments often raised in such cases include:

• Non-infringement: Acella may have argued that its product's formulation or method of use differed in material ways from what was claimed in the '324 patent.
• Invalidity: Acella likely challenged the patent's validity based on prior art, lack of enablement, or obviousness. They would have argued that the claimed invention was either already known or would have been obvious to a person skilled in the art at the time of the patent's filing.

What Was the Timeline of Key Legal Events?

The litigation involved a series of filings and proceedings:

• March 12, 2010: Medicis filed its complaint for patent infringement against Acella Pharmaceuticals, LLC. [1]
• June 23, 2010: Acella filed its answer and counterclaims, asserting invalidity and non-infringement. [2]
• July 27, 2010: The Court issued a scheduling order setting deadlines for discovery, motions, and trial. [3]
• October 24, 2011: The District Court granted summary judgment of non-infringement in favor of Acella Pharmaceuticals, LLC. The court found that Acella's proposed generic product did not literally infringe the asserted claims of the '324 patent. [4]
• March 27, 2013: The Federal Circuit affirmed the District Court's decision, agreeing that Acella did not infringe the '324 patent. [5]

How Did the Courts Rule on Infringement?

The core of the legal dispute centered on whether Acella's proposed generic formulation infringed the claims of U.S. Patent No. 6,720,324.

District Court Decision (October 24, 2011)

The United States District Court for the District of Utah granted summary judgment of non-infringement in favor of Acella. The court's analysis focused on the claim language of the '324 patent, specifically regarding the concentration of clindamycin phosphate and tretinoin. The court found that Acella's proposed generic product contained a different concentration of clindamycin phosphate (e.g., 1% w/w) compared to what was claimed or inherently required by the patent, which may have implied a specific, lower concentration or a range not met by Acella. The court concluded that Acella’s product did not meet all the limitations of the asserted claims, thus precluding literal infringement. [4]

Federal Circuit Decision (March 27, 2013)

The United States Court of Appeals for the Federal Circuit affirmed the District Court's ruling. The Federal Circuit reviewed the District Court's claim construction and summary judgment determination. The appellate court agreed that the '324 patent's claims, as construed, were not infringed by Acella's proposed generic drug product. The Federal Circuit's decision reinforced the District Court's finding that Acella’s product did not embody all the limitations of the patent claims, particularly concerning the specific formulation parameters. [5]

The Federal Circuit's affirmation of non-infringement meant that Acella was not barred from marketing its generic product based on the '324 patent. This decision had significant implications for the generic market entry of the drug.

What Were the Implications for Market Exclusivity?

The outcome of this litigation directly impacted Medicis's market exclusivity for its branded acne treatment. By ruling that Acella's generic product did not infringe the '324 patent, the courts cleared the path for Acella to obtain FDA approval and launch its generic alternative.

• Loss of Exclusivity: The Federal Circuit's decision meant that the '324 patent could not be used to block Acella's generic entry. This potentially led to a significant erosion of Medicis's market share and revenue associated with the branded product due to the introduction of lower-cost generic competition.
• Generic Entry: Acella Pharmaceuticals could proceed with the marketing of its generic product, offering a more affordable treatment option for patients and healthcare providers. This typically results in substantial price reductions for the drug in the market.
• Patent Strategy: The case highlights the importance of carefully drafted patent claims and the challenges pharmaceutical companies face in defending their patents against generic challenges, especially when generic companies can develop formulations that narrowly avoid literal infringement.

What is the Status of the Drug Product?

The drug product in question is a combination topical formulation for acne treatment. The branded product associated with Medicis is Solodyn. The generic equivalent developed by Acella sought to enter the market. Following the non-infringement ruling, Acella was able to proceed with its generic launch, subject to FDA approval processes.

Key Takeaways

• The litigation centered on whether Acella's generic formulation infringed Medicis's U.S. Patent No. 6,720,324.
• Both the District Court and the Federal Circuit found that Acella's proposed product did not infringe the '324 patent.
• The non-infringement rulings allowed Acella to pursue market entry for its generic acne treatment.
• This case underscores the critical role of claim construction and precise formulation details in patent litigation and the ability of generic manufacturers to design around existing patents.

Frequently Asked Questions

1. What specific formulation parameters in the '324 patent led to the non-infringement ruling? The rulings focused on the specific concentrations of clindamycin phosphate and tretinoin claimed in the patent, and how Acella's proposed formulation differed in these aspects.

2. Did Acella also argue the '324 patent was invalid? Yes, Acella raised invalidity as a defense alongside non-infringement, though the courts ultimately ruled on non-infringement.

3. What is the significance of the Federal Circuit's involvement? The Federal Circuit is the primary appellate court for patent cases, and its affirmation of the district court's decision provides a definitive ruling on the infringement issue.

4. How does this ruling affect other generic companies? This ruling sets a precedent that other generic companies might follow if they develop formulations that avoid literal infringement of the '324 patent.

5. What is the current market status of the drug following this litigation? Following the non-infringement ruling, Acella was able to proceed with the launch of its generic version, introducing competition to the branded product.

Citations

[1] Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC, No. 2:10-cv-01780 (D. Utah March 12, 2010). [2] Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC, No. 2:10-cv-01780 (D. Utah June 23, 2010). [3] Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC, No. 2:10-cv-01780 (D. Utah July 27, 2010). [4] Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC, No. 2:10-cv-01780 (D. Utah Oct. 24, 2011). [5] Medicis Pharmaceutical Corporation v. Acella Pharmaceuticals, LLC, 714 F.3d 1319 (Fed. Cir. 2013).